Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti–Interleukin-2 Receptor Antibody (Daclizumab)

Figure. Fifteen patients with pure red-cell aplasia were treated with daclizumab, 1 mg/kg of body weight, as described in the Methods section. Reticulocyte count, hemoglobin level, and transfusion history are seen for each patient. To convert hemoglobin values from g/dL to g/L, multiply value by 10.
Figure. Fifteen patients with pure red-cell aplasia were treated with daclizumab, 1 mg/kg of body weight, as described in the Methods section. Reticulocyte count, hemoglobin level, and transfusion history are seen for each patient. To convert hemoglobin values from g/dL to g/L, multiply value by 10. Clinical course of 6 responding patients after daclizumab treatment.

This Article

  1. Ann Intern Med February 7, 2006 vol. 144 no. 3 181-185
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. December 1, 2009, 151 (11)
  1. Alert me to current issues